Natixis Advisors LLC Has $6.68 Million Stock Position in Halozyme Therapeutics, Inc. $HALO

Natixis Advisors LLC decreased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 13.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 99,296 shares of the biopharmaceutical company’s stock after selling 15,032 shares during the period. Natixis Advisors LLC’s holdings in Halozyme Therapeutics were worth $6,683,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of HALO. Measured Wealth Private Client Group LLC grew its stake in shares of Halozyme Therapeutics by 51.5% in the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 124 shares during the last quarter. Larson Financial Group LLC lifted its position in Halozyme Therapeutics by 3,118.2% in the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 343 shares during the period. Clearstead Advisors LLC lifted its position in Halozyme Therapeutics by 107.7% in the third quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 265 shares during the period. Harbour Investments Inc. lifted its position in Halozyme Therapeutics by 152.5% in the fourth quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 372 shares during the period. Finally, Penserra Capital Management LLC bought a new position in Halozyme Therapeutics in the third quarter worth $52,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Activity

In other news, Director Bernadette Connaughton sold 1,625 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $66.21, for a total value of $107,591.25. Following the sale, the director owned 43,669 shares in the company, valued at approximately $2,891,324.49. The trade was a 3.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 10,000 shares of the business’s stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $69.07, for a total transaction of $690,700.00. Following the completion of the sale, the chief executive officer owned 767,780 shares in the company, valued at $53,030,564.60. This represents a 1.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 102,107 shares of company stock worth $6,898,834. Corporate insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $71.53 on Monday. Halozyme Therapeutics, Inc. has a 52 week low of $51.06 and a 52 week high of $82.22. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. The company’s fifty day moving average is $66.79 and its 200-day moving average is $68.72. The company has a market capitalization of $8.48 billion, a PE ratio of 25.73, a P/E/G ratio of 0.30 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, beating the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The company had revenue of $376.71 million for the quarter, compared to the consensus estimate of $358.60 million. During the same quarter in the previous year, the company earned $1.11 EPS. The firm’s revenue for the quarter was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Equities research analysts predict that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current fiscal year.

Key Stories Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Zacks Research raised Halozyme’s earnings estimates across multiple future periods, including FY2026, FY2027, and FY2028, signaling confidence in the company’s longer-term profit growth. Halozyme Therapeutics article
• Positive Sentiment: Analysts also increased estimates for several individual quarters in 2027, reinforcing a constructive earnings outlook for Halozyme Therapeutics. Halozyme Therapeutics article
• Neutral Sentiment: One near-term forecast was trimmed slightly and another was revised lower, but the overall analyst tone remains mostly favorable. Halozyme Therapeutics article
• Neutral Sentiment: Recent insider selling by the CEO was disclosed, but the trades were executed under a pre-arranged trading plan, which typically lessens investor concern. Halozyme Therapeutics article

Analyst Upgrades and Downgrades

Several research analysts recently commented on HALO shares. TD Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. Weiss Ratings raised Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. HC Wainwright raised their target price on Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Wells Fargo & Company raised their target price on Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 19th. Finally, Wall Street Zen raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Eight research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $81.60.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.